ARTICLE | Company News

Eyetech, SurModics deal

October 25, 2010 7:00 AM UTC

Eyetech and SurModics resumed development of an extended-release formulation of age-related macular degeneration (AMD) drug Macugen pegaptanib under a 2005 deal. SurModics will use its microparticles technology to develop the new formulation, after which Eyetech will be responsible for all further development and commercialization. SurModics is eligible for milestones and royalties. Further terms were not disclosed. ...